Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Swedish Orphan Biovitrum AB (publ)

Healthcare US BIOVF

47.475USD
0.00(0%)

Last update at 2026-06-02T20:00:00Z

Day Range

47.3547.35
LowHigh

52 Week Range

27.0642.22
LowHigh

Fundamentals

  • Previous Close 47.48
  • Market Cap14348.70M
  • Volume200
  • P/E Ratio275.47
  • Dividend Yield-%
  • EBITDA11362.00M
  • Revenue TTM27852.00M
  • Revenue Per Share TTM81.01
  • Gross Profit TTM 21768.00M
  • Diluted EPS TTM0.15

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 33.91M 4407.00M 2954.00M 3321.00M 3295.00M
Minority interest 2.00M 6.00M 0.00000M - -
Net income 476.80M 3885.00M 2409.00M 2638.00M 2679.00M
Selling general administrative 11144.00M 7553.00M 10161.00M 7847.00M 6294.00M
Selling and marketing expenses - 3532.00M 3483.00M - -
Gross profit 12289.09M 20242.00M 17128.00M 14014.00M 12045.00M
Reconciled depreciation 10096.00M 3679.00M 2827.00M 2419.00M 2006.00M
Ebit 864.83M 5625.00M 4065.00M 3813.00M 3733.00M
Ebitda 10935.50M 9304.00M 7234.00M 6198.00M 5776.00M
Depreciation and amortization 10070.67M 3679.00M 3169.00M 2385.00M 2043.00M
Non operating income net other - - - - -
Operating income 8027.81M 5625.00M 4066.00M 3813.00M 3733.00M
Other operating expenses 20139.35M 20402.00M 18057.00M 14945.00M 11742.00M
Interest expense 828.92M 1239.00M 1111.00M 458.00M 419.00M
Tax provision -442.00000M 528.00M 714.00M 683.00M 616.00M
Interest income 22.00M 32.00M 27.00M 5.00M 0.00000M
Net interest income -831.00000M -1219.00000M -878.00000M -481.00000M -454.00000M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -440.89123M 528.00M 546.00M 683.00M 616.00M
Total revenue 28167.16M 26027.00M 22123.00M 18790.00M 15529.00M
Total operating expenses 4261.28M 14617.00M 13062.00M 10169.00M 8258.00M
Cost of revenue 15878.07M 5785.00M 4995.00M 4776.00M 3484.00M
Total other income expense net -7993.89666M -1218.00000M -1112.00000M -492.00000M -438.00000M
Discontinued operations - - - - -
Net income from continuing ops 476.00M 3879.00M 2769.00M 2638.00M 2679.00M
Net income applicable to common shares - - - 2638.00M 2679.00M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 67264.84M 75444.00M 74027.00M 52496.00M 48661.00M
Intangible assets 39955.52M 48515.00M 49341.00M 33006.00M 32135.00M
Earning assets - - - - -
Other current assets -0.00100M 1.00M 7893.00M 123.00M 1.00M
Total liab 29636.47M 35149.00M 40160.00M 25971.00M 25458.00M
Total stockholder equity 37622.39M 40286.00M 33867.00M 26525.00M 23203.00M
Deferred long term liab - - - - 517.00M
Other current liab 8755.98M 7596.00M 9036.00M 7676.00M 1041.00M
Common stock 195.51M 195.00M 194.00M 170.00M 169.00M
Capital stock 196.00M 195.00M 194.00M 170.00M 169.00M
Retained earnings 22345.80M 21924.00M 18055.00M 15793.00M 13155.00M
Other liab - - - 7943.00M 7673.00M
Good will 9001.36M 10456.00M 9642.00M 7007.00M 6288.00M
Other assets - - - 1.00M 1338.00M
Cash 1038.39M 1140.00M 904.00M 1361.00M 1045.00M
Cash and equivalents - - - - -
Total current liabilities 16028.69M 12600.00M 19095.00M 14857.00M 8761.00M
Current deferred revenue - - 2904.00M - 5280.00M
Net debt 10686.13M 15595.00M 19581.00M 7739.00M 9861.00M
Short term debt 6040.81M 4060.00M 8961.00M 5929.00M 1882.00M
Short long term debt 5942.00M 3926.00M 8813.00M 5795.00M 1768.00M
Short long term debt total 11724.51M 16735.00M 20485.00M 9100.00M 10906.00M
Other stockholder equity 15081.07M 18167.00M 15618.00M 10562.00M 9879.00M
Property plant equipment - - - 274.00M 493.00M
Total current assets 14491.56M 13162.00M 12671.00M 11210.00M 8778.00M
Long term investments - - - - -
Net tangible assets - - - -13488.00000M -14704.00000M
Short term investments - - 105.00M - -9.00000M
Net receivables 8339.03M 7862.00M 7062.00M 5248.00M 4308.00M
Long term debt 5180.00M 12407.00M 11356.00M 2971.00M 8777.00M
Inventory 5114.14M 4159.00M 3874.00M 3332.00M 3424.00M
Accounts payable 1231.90M 944.00M 1024.00M 1252.00M 558.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - -934.00000M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 211.47M 398.00M 2085.00M 121.00M 1.00M
Deferred long term asset charges - - - - -
Non current assets total 52773.28M 62282.00M 61356.00M 41285.00M 39883.00M
Capital lease obligations 373.00M 402.00M 316.00M 334.00M 361.00M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -41.00000M -3091.00000M -21509.00000M -1477.00000M -367.00000M
Change to liabilities - - - 0.00000M 0.00000M
Total cashflows from investing activities -4283.22838M -3091.00000M -21904.00000M -1477.00000M -367.00000M
Net borrowings -4933.00000M -4436.00000M 11248.00M -2553.00000M -4123.00000M
Total cash from financing activities -4312.15563M -4001.00000M 17012.00M -2991.00000M -4474.00000M
Change to operating activities - - - -807.00000M 980.00M
Net income 476.80M 4407.00M 2954.00M 3321.00M 3295.00M
Change in cash 92.52M 236.00M -457.00000M 316.00M 641.00M
Begin period cash flow 945.87M 904.00M 1361.00M 1045.00M 404.00M
End period cash flow 1038.39M 1140.00M 904.00M 1361.00M 1045.00M
Total cash from operating activities 8542.52M 7388.00M 4470.00M 4665.00M 5470.00M
Issuance of capital stock 245.00M 427.00M 6129.00M - -
Depreciation 10070.67M 3679.00M 3200.00M 2419.00M 2006.00M
Other cashflows from investing activities -95.75918M -2921.00000M -4536.00000M - -
Dividends paid - - - - -
Change to inventory -1077.00000M -159.00000M 286.00M 413.00M -318.00000M
Change to account receivables - -178.00000M -901.00000M -1982.00000M 452.00M
Sale purchase of stock - - - - -
Other cashflows from financing activities 364.08M 8.00M -365.00000M 13103.00M 13717.00M
Change to netincome - - - 556.00M -322.00000M
Capital expenditures 39.90M 3005.00M 4943.00M 1477.00M 370.00M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -506.72567M -179.00000M -1160.00000M -806.00000M 1114.00M
Stock based compensation 250.00M 218.00M 298.00M - -
Other non cash items -1498.23219M -519.00000M -524.00000M -269.00000M -945.00000M
Free cash flow 8502.62M 4383.00M -473.00000M 3188.00M 5100.00M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BIOVF
Swedish Orphan Biovitrum AB (publ)		 - -% 47.48 275.47 23.09 4.50 3.35 5.49 14.18
ZTS
Zoetis Inc		 1.20 1.57% 77.59 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 0.58 1.91% 31.01 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 - -% 153.91 21.73 14.95 3.16 2.15 3.56 12.82
GALDY
GALDERMA GROUP AG		 -0.79 1.89% 40.92 74.21 41.67 8.64 5.55 9.15 42.22

Reports Covered

Stock Research & News

View All

Profile

Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocytopenia and thrombocytopenia; Elocta/Eloctate for the treatment and prophylaxis of bleeding in patients with haemophilia A; Gamifant for treating hemophagocytic lymphohistiocytosis; Kineret for the treatment of cryopyrin-associated periodic syndrome, rheumatoid arthritis, familial Mediterranean fever, deficiency of interleukin-1 receptor antagonist, and systemic juvenile idiopathic arthritis; Orfadin for hereditary tyrosinemia type 1 and alkaptonuria; Synagis for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus in infants and young children; VONJO, a kinase inhibitor indicated for the treatment of post-polycythemia vera or post-essential thrombocythemia myelofibrosis; and Zynlonta for treating adult patients with relapsed or refractory diffuse large and high grade B-cell lymphoma. The company also provides other medicines, such as Akynzeo, Jyseleca, Tegsedi, and Waylivra, as well as develops drug substances for ReFacto AF/Xyntha for Pfizer. The company has collaboration agreements with Sanofi, Apellis Pharmaceuticals, Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. The company was incorporated in 1939 and is headquartered in Stockholm, Sweden.

Swedish Orphan Biovitrum AB (publ)

Norra Stationsgatan 93A, Stockholm, Sweden

Key Executives

Name Title Year Born
Dr. Guido Oelkers CEO & Pres 1965
Dr. Anders Ullman M.D., Ph.D. Head of R&D & Medical Affairs and Chief Medical Officer 1956
Mr. Henrik Stenqvist Chief Financial Officer 1968
Ms. Christine Wesstrom Head of Technical Operations 1975
Mr. Thomas Kudsk Larsen Head of Communication & Investor Relations 1974
Mr. Torbjörn Hallberg Gen. Counsel and Head of Legal Affairs & HR 1969
Mr. Daniel Rankin Head of Strategy & Corp. Devel. 1980
Pablo de Mora Head of Global Marketing & Access 1968
Mr. Philip Wood Head of Haematology 1968
Ms. Konstantina Karampela Sr. Director of European Commercial Operations (Specialty Care and Partner Products) NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions